151 related articles for article (PubMed ID: 38642218)
21. Comparison of the measurement properties of the EQ-5D-5L and SF-6Dv2 among overweight and obesity populations in China.
Xie S; Li M; Wang D; Hong T; Guo W; Wu J
Health Qual Life Outcomes; 2023 Oct; 21(1):118. PubMed ID: 37904216
[TBL] [Abstract][Full Text] [Related]
22. Health utilities in cancer patients: A study protocol for a prospective, longitudinal cohort using online survey.
Poder TG; Carrier N; McFadden N; Pavic M
Medicine (Baltimore); 2019 Mar; 98(9):e14647. PubMed ID: 30817585
[TBL] [Abstract][Full Text] [Related]
23. A Comparison of the SF-6Dv2 and SF-6D UK Utility Values in a Mixed Patient and Healthy Population.
McDool E; Mukuria C; Brazier J
Pharmacoeconomics; 2021 Aug; 39(8):929-940. PubMed ID: 34043147
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the EQ-5D 3L and the SF-6D (SF-36) contemporaneous utility scores in patients with chronic kidney disease in Sri Lanka: a cross-sectional survey.
Kularatna S; Senanayake S; Gunawardena N; Graves N
BMJ Open; 2019 Feb; 9(2):e024854. PubMed ID: 30772857
[TBL] [Abstract][Full Text] [Related]
25. Comparative performance and mapping algorithms between EQ-5D-5L and SF-6Dv2 among the Chinese general population.
Xie S; Wu J; Chen G
Eur J Health Econ; 2024 Feb; 25(1):7-19. PubMed ID: 36709458
[TBL] [Abstract][Full Text] [Related]
26. Development of the SF-6Dv2 health utility survey: comprehensibility and patient preference.
Broderick L; Bjorner JB; Lauher-Charest M; White MK; Kosinski M; Mulhern B; Brazier J
J Patient Rep Outcomes; 2022 May; 6(1):47. PubMed ID: 35551545
[TBL] [Abstract][Full Text] [Related]
27. Valuing SF-6Dv2 in Australia Using an International Protocol.
Mulhern B; Norman R; Brazier J
Pharmacoeconomics; 2021 Oct; 39(10):1151-1162. PubMed ID: 34250578
[TBL] [Abstract][Full Text] [Related]
28. Quality of life of the Canadian population using the VR-12: population norms for health utility values, summary component scores and domain scores.
Trenaman L; Guh D; Bansback N; Sawatzky R; Sun H; Cuthbertson L; Whitehurst DGT
Qual Life Res; 2024 Feb; 33(2):453-465. PubMed ID: 37938404
[TBL] [Abstract][Full Text] [Related]
29. Mapping IWQOL-Lite onto EQ-5D-5L and SF-6Dv2 among overweight and obese population in China.
Guo W; Xie S; Wang D; Wu J
Qual Life Res; 2024 Mar; 33(3):817-829. PubMed ID: 38167749
[TBL] [Abstract][Full Text] [Related]
30. [SENTIERI - Epidemiological Study of Residents in National Priority Contaminated Sites. Sixth Report].
Zona A; Fazzo L; Benedetti M; Bruno C; Vecchi S; Pasetto R; Minichilli F; De Santis M; Nannavecchia AM; Di Fonzo D; Contiero P; Ricci P; Bisceglia L; Manno V; Minelli G; Santoro M; Gorini F; Ancona C; Scondotto S; Soggiu ME; Scaini F; Beccaloni E; Marsili D; Villa MF; Maifredi G; Magoni M; Iavarone I;
Epidemiol Prev; 2023; 47(1-2 Suppl 1):1-286. PubMed ID: 36825373
[TBL] [Abstract][Full Text] [Related]
31. Predicting SF-6D from the European Organization for Treatment and Research of Cancer Quality of Life Questionnaire scores in patients with colorectal cancer.
Wong CK; Lam CL; Wan YF; Rowen D
Value Health; 2013; 16(2):373-84. PubMed ID: 23538190
[TBL] [Abstract][Full Text] [Related]
32. Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D.
Teckle P; McTaggart-Cowan H; Van der Hoek K; Chia S; Melosky B; Gelmon K; Peacock S
Health Qual Life Outcomes; 2013 Dec; 11():203. PubMed ID: 24289488
[TBL] [Abstract][Full Text] [Related]
33. Health State Utilities for Patient's Current Health from Bipolar Type I Disorder.
Banihashemian M; Rashidian A; Gholamian F; Parsaeian M; Moradi N; Amini H
J Ment Health Policy Econ; 2018 Mar; 21(1):3-10. PubMed ID: 29643263
[TBL] [Abstract][Full Text] [Related]
34. Health-related quality of life among Indian population: The EQ-5D population norms for India.
Jyani G; Prinja S; Garg B; Kaur M; Grover S; Sharma A; Goyal A
J Glob Health; 2023 Feb; 13():04018. PubMed ID: 36799239
[TBL] [Abstract][Full Text] [Related]
35. A comparison of utility measurement using EQ-5D and SF-6D preference-based generic instruments in patients with rheumatoid arthritis.
Salaffi F; Carotti M; Ciapetti A; Gasparini S; Grassi W
Clin Exp Rheumatol; 2011; 29(4):661-71. PubMed ID: 21813061
[TBL] [Abstract][Full Text] [Related]
36. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
37. Health-related quality of life among adults with haemophilia in China: A comparison with age-matched general population.
Zhang W; Xie S; Xue F; Liu W; Chen L; Zhang L; Wu J; Yang R
Haemophilia; 2022 Sep; 28(5):776-783. PubMed ID: 35751903
[TBL] [Abstract][Full Text] [Related]
38. Catalog and comparison of societal preferences (utilities) for lung cancer health states: results from the Cancer Care Outcomes Research and Surveillance (CanCORS) study.
Tramontano AC; Schrag DL; Malin JK; Miller MC; Weeks JC; Swan JS; McMahon PM
Med Decis Making; 2015 Apr; 35(3):371-87. PubMed ID: 25670839
[TBL] [Abstract][Full Text] [Related]
39. Interchangeability of the EQ-5D and the SF-6D, and comparison of their psychometric properties in a spinal postoperative Spanish population.
Selva-Sevilla C; Ferrara P; Gerónimo-Pardo M
Eur J Health Econ; 2020 Jun; 21(4):649-662. PubMed ID: 32065301
[TBL] [Abstract][Full Text] [Related]
40. Magnitude and meaningfulness of change in SF-36 scores in four types of orthopedic surgery.
Busija L; Osborne RH; Nilsdotter A; Buchbinder R; Roos EM
Health Qual Life Outcomes; 2008 Jul; 6():55. PubMed ID: 18667085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
